Neil M.H. Graham

33.8k total citations · 13 hit papers
240 papers, 16.4k citations indexed

About

Neil M.H. Graham is a scholar working on Physiology, Infectious Diseases and Dermatology. According to data from OpenAlex, Neil M.H. Graham has authored 240 papers receiving a total of 16.4k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Physiology, 63 papers in Infectious Diseases and 56 papers in Dermatology. Recurrent topics in Neil M.H. Graham's work include Asthma and respiratory diseases (88 papers), Dermatology and Skin Diseases (56 papers) and Allergic Rhinitis and Sensitization (42 papers). Neil M.H. Graham is often cited by papers focused on Asthma and respiratory diseases (88 papers), Dermatology and Skin Diseases (56 papers) and Allergic Rhinitis and Sensitization (42 papers). Neil M.H. Graham collaborates with scholars based in United States, France and Germany. Neil M.H. Graham's co-authors include Gianluca Pirozzi, George D. Yancopoulos, Denise L. Jacobson, N R Rose, Stephen J. Gange, Neil Stahl, Jennifer D. Hamilton, Allen Radin, Alfred J. Saah and Marius Ardeleanu and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Neil M.H. Graham

236 papers receiving 15.9k citations

Hit Papers

Epidemiology and Estimated Population Burden of Selected ... 1993 2026 2004 2015 1997 2014 2013 2016 2016 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Epidemiology and Estimated Population Burden of Selected Autoimmune Diseases in the United States
    1997 1.2k citations Denise L. Jacobson, Neil M.H. Graham et al. profile →
  2. Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
    2014 1.0k citations Lisa A. Beck, Diamant Thaçi et al. New England Journal of Medicine profile →
  3. Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
    2013 951 citations Sally E. Wenzel, Ross E. Rocklin et al. New England Journal of Medicine profile →
  4. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
    2016 632 citations Sally E. Wenzel, Gianluca Pirozzi et al. profile →
  5. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis
    2016 553 citations Claus Bachert, Leda Mannent et al. profile →
  6. Targeting key proximal drivers of type 2 inflammation in disease
    2015 529 citations Neil M.H. Graham, Gianluca Pirozzi et al. profile →
  7. Dementia in AIDS patients
    1993 524 citations Neil M.H. Graham, Lisa P. Jacobson et al. profile →
  8. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis
    2018 477 citations Emma Guttman‐Yassky, Robert Bissonnette et al. profile →
  9. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation
    1996 392 citations Neil M.H. Graham, David Vlahov et al. profile →
  10. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis
    2014 359 citations Jennifer D. Hamilton, Mayte Suárez‐Fariñas et al. profile →
  11. Commonality of the IL-4/IL-13 pathway in atopic diseases
    2017 349 citations Gianluca Pirozzi, Neil M.H. Graham et al. profile →
  12. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t
    2017 344 citations Marjolein de Bruin‐Weller, Diamant Thaçi et al. British Journal of Dermatology profile →
  13. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis
    2019 231 citations Gil Yosipovitch, Laurent Eckert et al. British Journal of Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Neil M.H. Graham United States 62 5.2k 4.5k 4.3k 3.3k 2.9k 240 16.4k
A.Y. Finlay United Kingdom 70 2.7k 0.5× 4.6k 1.0× 15.1k 3.5× 1.1k 0.3× 6.7k 2.3× 273 22.5k
Sinéad Langan United Kingdom 48 2.0k 0.4× 2.8k 0.6× 5.5k 1.3× 418 0.1× 2.1k 0.7× 214 13.8k
Harald Renz Germany 63 4.6k 0.9× 3.2k 0.7× 1.9k 0.4× 1.8k 0.6× 3.4k 1.2× 310 13.7k
Luigi Naldi Italy 62 984 0.2× 1.0k 0.2× 6.5k 1.5× 717 0.2× 4.1k 1.4× 316 15.4k
Kam‐Lun Ellis Hon Hong Kong 47 1.1k 0.2× 2.0k 0.4× 2.8k 0.6× 1.1k 0.3× 442 0.2× 384 7.6k
Ulrich Wahn Germany 79 12.5k 2.4× 13.0k 2.9× 6.6k 1.5× 804 0.2× 1.9k 0.7× 383 21.2k
Andrew J. Wardlaw United Kingdom 82 19.5k 3.8× 5.7k 1.3× 928 0.2× 943 0.3× 8.3k 2.9× 267 27.2k
C. Paul France 68 1.9k 0.4× 2.7k 0.6× 8.8k 2.0× 507 0.2× 8.8k 3.0× 420 16.5k
Mimi L.K. Tang Australia 74 4.9k 1.0× 8.7k 1.9× 2.8k 0.7× 691 0.2× 4.4k 1.5× 403 19.6k
L. Puig Spain 57 2.2k 0.4× 1.1k 0.2× 7.7k 1.8× 572 0.2× 11.2k 3.8× 626 18.2k

Countries citing papers authored by Neil M.H. Graham

Since Specialization
Citations

This map shows the geographic impact of Neil M.H. Graham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil M.H. Graham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil M.H. Graham more than expected).

Fields of papers citing papers by Neil M.H. Graham

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil M.H. Graham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil M.H. Graham. The network helps show where Neil M.H. Graham may publish in the future.

Co-authorship network of co-authors of Neil M.H. Graham

This figure shows the co-authorship network connecting the top 25 collaborators of Neil M.H. Graham. A scholar is included among the top collaborators of Neil M.H. Graham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil M.H. Graham. Neil M.H. Graham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Turner, Anthony, et al.. (2025). Lowering the maximum legal tackle height in Scottish community women’s rugby: an injury surveillance and video analysis study across two seasons. BMJ Open Sport & Exercise Medicine. 11(2). e002499–e002499. 1 indexed citations
2.
Graham, Neil M.H., et al.. (2025). Lowered tackle height law variation in Scottish men’s community rugby: a video analysis evaluation of 18 702 tackles across two seasons. BMJ Open Sport & Exercise Medicine. 11(2). e002492–e002492. 1 indexed citations
3.
Tohda, Yuji, Yoichi Nakamura, Takao Fujisawa, et al.. (2020). Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study. Allergology International. 69(4). 578–587. 15 indexed citations
4.
Beck, Lisa A., Jonathan I. Silverberg, Eric L. Simpson, et al.. (2020). Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trials. Journal of the European Academy of Dermatology and Venereology. 35(2). e130–e133. 9 indexed citations
5.
Bachert, Claus, Peter W. Hellings, Joaquim Mullol, et al.. (2019). Dupilumab improves health‐related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy. 75(1). 148–157. 74 indexed citations
6.
Eichenfield, Lawrence F., Thomas Bieber, Lisa A. Beck, et al.. (2019). Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. American Journal of Clinical Dermatology. 20(3). 443–456. 114 indexed citations
7.
Wollenberg, Andreas, Lisa A. Beck, Andrew Blauvelt, et al.. (2019). Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). British Journal of Dermatology. 182(5). 1120–1135. 91 indexed citations
8.
Ariëns, Lieneke F.M., Abhijit Gadkari, Harmieke van Os‐Medendorp, et al.. (2019). Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index. Acta Dermato Venereologica. 99(10). 851–857. 14 indexed citations
9.
Callewaert, Chris, Teruaki Nakatsuji, Rob Knight, et al.. (2019). IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis. Journal of Investigative Dermatology. 140(1). 191–202.e7. 158 indexed citations
10.
Paller, Amy S., Ashish Bansal, Eric L. Simpson, et al.. (2019). Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. American Journal of Clinical Dermatology. 21(1). 119–131. 55 indexed citations
11.
Wenzel, Sally E., Ian Pavord, Jaman Maroni, et al.. (2018). Type 2 Biomarkers Associated with Dupilumab Efficacy in Patients with Uncontrolled, Moderate-To-Severe Asthma Enrolled in the Phase 3 Study LIBERTY ASTHMA QUEST. American Journal of Respiratory and Critical Care Medicine. 197. 12 indexed citations
12.
Beck, Lisa A., et al.. (2017). 251 Treatment interruption did not impact efficacy or long-term safety of dupilumab: A phase 3 open-label trial. Journal of Investigative Dermatology. 137(5). S43–S43. 1 indexed citations
13.
14.
Beck, Lisa A., Diamant Thaçi, Jennifer D. Hamilton, et al.. (2014). Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis. New England Journal of Medicine. 371(2). 130–139. 1008 indexed citations breakdown →
15.
16.
Jacobson, Denise L., Lígia Peralta, Mychelle Farmer, et al.. (2000). Relationship of Hormonal Contraception and Cervical Ectopy as Measured by Computerized Planimetry to Chlamydial Infection in Adolescents. Sexually Transmitted Diseases. 27(6). 313–319. 42 indexed citations
17.
Sterling, Timothy R., Richard D. Moore, Neil M.H. Graham, et al.. (1998). Mycobacterium tuberculosis infection and disease are not associated with protection against subsequent disseminated M. avium complex disease. AIDS. 12(12). 1451–1457. 7 indexed citations
18.
19.
Jacobson, Lisa P., Lewis K. Schrager, Nancy Kass, et al.. (1994). Impact of immunosuppression on health care use by men in the Multicenter AIDS Cohort Study (MACS).. PubMed. 7(6). 607–16. 18 indexed citations
20.
Caiaffa, Waleska Teixeira, David Vlahov, Neil M.H. Graham, et al.. (1994). Drug Smoking, Pneumocystis Carinii Pneumonia, and Immunosuppression Increase Risk of Bacterial Pneumonia in Human Immunodeficiency Virus-Seropositive Injection Drug Users. American Journal of Respiratory and Critical Care Medicine. 150(6). 1493–1498. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A.Y. Finlay Breakdown of academic impact, for papers by Sinéad Langan Breakdown of academic impact, for papers by Harald Renz Breakdown of academic impact, for papers by Luigi Naldi Breakdown of academic impact, for papers by Kam‐Lun Ellis Hon Breakdown of academic impact, for papers by Ulrich Wahn Breakdown of academic impact, for papers by Andrew J. Wardlaw Breakdown of academic impact, for papers by C. Paul Breakdown of academic impact, for papers by Mimi L.K. Tang Breakdown of academic impact, for papers by L. Puig
Rankless by CCL
2026